Related Experiment Video
Updated: Oct 23, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate
Ekaterina Raykova1, Mohammad Farmahini Farahani2,3, Stanislava Ivanova4
1Phase I Clinical Research Unit, Comac Medical Ltd., Sofia, Bulgaria.
Background:
P044 is a proposed biosimilar candidate of Teriparatide for reference medicine, Forsteo®. This study was designed to evaluate the Pharmacokinetic/Pharmacodynamic (PK/PD) bioequivalence between P044 and Forsteo®.
Methods:
In this randomized, open-label, single-dose, crossover study, 66 healthy female subjects were randomized to receive P044 and Forsteo®. The primary PK endpoints of the study were the area under the concentration versus time from zero to infinity (AUC0-inf) and maximum plasma concentration (Cmax). Secondary endpoints included area under the concentration versus time from zero to the last quantifiable concentration (AUC0-last) and Cmax for PD parameter, additional PK parameters and safety.
Results:
Sixty-six subjects were enrolled in the study and baseline demographics were similar between the two treatments. The two treatments presented similar PK/PD parameters and the 90% confidence interval for primary and secondary endpoints were within the bioequivalence acceptance range (80.00-125.00%) for all parameters. None of the subjects experienced serious adverse event, and all of the reported adverse events were mild and similar between two treatments.
Conclusions:
This study demonstrated the PK/PD similarity of P044 to reference medicine, Forsteo® and safety profiles were comparable between treatments.
Trial Registration:
EudraCT Number: 2019-004477-82.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation
Measurement of Bioavailability: Pharmacodynamic Methods